These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1171 related articles for article (PubMed ID: 19228077)

  • 61. Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
    Jain L; Woo S; Gardner ER; Dahut WL; Kohn EC; Kummar S; Mould DR; Giaccone G; Yarchoan R; Venitz J; Figg WD
    Br J Clin Pharmacol; 2011 Aug; 72(2):294-305. PubMed ID: 21392074
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
    Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
    Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
    Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
    Weintraub JL; Salem R
    J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
    Li Y; Huang JW; Lu LG; Shao PJ; Hu BS; Huang GM; Wei ZG; Zhang L
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2187-92. PubMed ID: 21029658
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
    Cheng AL; Kang YK; He AR; Lim HY; Ryoo BY; Hung CH; Sheen IS; Izumi N; Austin T; Wang Q; Greenberg J; Shiratori S; Beckman RA; Kudo M;
    J Hepatol; 2015 Oct; 63(4):896-904. PubMed ID: 26071796
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
    J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 70. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
    Srimuninnimit V; Sriuranpong V; Suwanvecho S
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):255-60. PubMed ID: 24810940
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
    Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
    Mir O; Coriat R; Blanchet B; Durand JP; Boudou-Rouquette P; Michels J; Ropert S; Vidal M; Pol S; Chaussade S; Goldwasser F
    PLoS One; 2012; 7(5):e37563. PubMed ID: 22666367
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
    Yau T; Chan P; Ng KK; Chok SH; Cheung TT; Fan ST; Poon RT
    Cancer; 2009 Jan; 115(2):428-36. PubMed ID: 19107763
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
    Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
    Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
    Strumberg D; Richly H; Hilger RA; Schleucher N; Korfee S; Tewes M; Faghih M; Brendel E; Voliotis D; Haase CG; Schwartz B; Awada A; Voigtmann R; Scheulen ME; Seeber S
    J Clin Oncol; 2005 Feb; 23(5):965-72. PubMed ID: 15613696
    [TBL] [Abstract][Full Text] [Related]  

  • 77. S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
    Kudo M; Moriguchi M; Numata K; Hidaka H; Tanaka H; Ikeda M; Kawazoe S; Ohkawa S; Sato Y; Kaneko S; Furuse J; Takeuchi M; Fang X; Date Y; Takeuchi M; Okusaka T
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):407-417. PubMed ID: 28497756
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
    Kelley RK; Verslype C; Cohn AL; Yang TS; Su WC; Burris H; Braiteh F; Vogelzang N; Spira A; Foster P; Lee Y; Van Cutsem E
    Ann Oncol; 2017 Mar; 28(3):528-534. PubMed ID: 28426123
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
    Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
    Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
    Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.